Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureMurali Janakiram
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
Teclistamab plus daratumumab in relapsed or refractory multiple myeloma
10.1056/nejmoa2514663 · 2026
Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: a systematic review and meta-analysis
10.1016/j.jgo.2023.101628 · 2024
Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: a CIBMTR analysis
10.1182/blood-2025-133 · 2025
Unresolved referenced work
Kept as external metadata until matched
CAR-T therapy is the preferred option in relapsed/refractory multiple myeloma
10.1182/bloodadvances.2026019898
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial
10.1016/s1470-2045(25)00653-9 · 2026
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
10.1038/s41375-022-01531-2 · 2022
Retreatment with anti-CD38-based combinations in multiple myeloma in real-life: results from the Emmy cohort study
10.1016/j.clml.2025.05.015 · 2025
CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies
10.1182/bloodadvances.2023010162 · 2023
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
10.1182/blood-2016-03-703439 · 2016
Safety and efficacy of standard of care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma
10.1182/blood.2024025945 · 2025
Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma
10.1038/s41408-024-01167-8 · 2024
CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53
10.1056/nejmoa2411507 · 2025
Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel
10.1038/s41408-024-01129-0 · 2024
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: a single-center experience
10.1038/s41408-023-00963-y · 2023
Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed/refractory myeloma patients treated with teclistamab: Implications for outpatient step-up dosing
10.1002/hem3.132 · 2024
Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels
10.1182/bloodadvances.2025016490 · 2025
Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed/refractory multiple myeloma
10.1182/blood-2025-5814 · 2025
International Myeloma Working Group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma
10.1038/s41375-024-02482-6 · 2025
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma
10.1038/s41591-023-02491-5 · 2023
No additional external references are available.